By Stephen Nakrosis
The American depositary receipts of Inventiva were trading higher in Wednesday’s after-hours market following news the biopharmaceutical company entered a licensing agreement with Hepalys to develop and commercialize Inventiva’s lanifibranor for the treatment of non-alcoholic steatohepatitis in Japan and South Korea.
Inventiva…
Read the full article here
